# HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Source: https://onco.cc/trials/nct05586074/  
OnCo record `nct05586074` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Clifutinib in acute myeloid leukaemia, now recruiting.

## Summary

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML is a phase 3 interventional study registered as NCT05586074, led by Sunshine Lake Pharma, and recruiting on the registry. Official title: HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia: a Multicenter, Open-label, Randomised Phase 3 Trial. Planned enrolment is 324 participants (estimated). The study started in 2023-03-03 and primary completion is expected in 2027-11-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05586074
- Phase: 3
- Setting: HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial
- Sponsor: Sunshine Lake Pharma
- Enrolled: 324

## Sources

- ClinicalTrials.gov NCT05586074: https://clinicaltrials.gov/study/NCT05586074

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [FLT3-mutated acute myeloid leukaemia](https://onco.cc/cancers/aml-flt3/)
- drugs: [Clifutinib](https://onco.cc/drugs/clifutinib/)
- companies: [Sunshine Lake Pharma (HEC)](https://onco.cc/companies/sunshine-lake-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05586074.json